AstraZeneca Pharma India Ltd said the company has obtained permission from the Drugs Controller General of India (DCGI) for import and marketing of Breztri Aerosphere, an inhalation preparation containing budesonide (160 mcg), glycopyrronium (7.2 mcg) and formoterol fumarate dihydrate (5 mcg).

This combination medication is used to treat chronic obstructive pulmonary disease (COPD) in adults, relieving symptoms and preventing exacerbations.

Regarding this, AstraZeneca Pharma India Limited announced that Breztri Aerosphere will be launched in India in January 2025.

“We refer to our earlier communication dated December 2, 2023, announcing receipt of import and marketing authorization in Form CT-20 from the Drug Controller General of India for Breztri Aerosphere,” the statement said. company in an exchange file.

The company’s sales for the quarter stood at ₹408 Crore, up 31.16% YoY. However, the profit declined by 26.62% to ₹38.43 Crore. Compared to the previous quarter, Astrazeneca Pharma India recorded a sales growth of 5.28% and a spectacular profit gain of 425.95%.

Operating profit improved significantly, increasing 284.62% quarter-over-quarter, despite a 34.06% year-on-year decline. EPS for the quarter was ₹15.37, down 5.48% from the previous year.

For comments and suggestions, write to us at [email protected]